Effectiveness of combined hepatoprotectors foresee in the treatment of chronic diffuse liver disease

Completed the study of the FORCELIV hepatoprotector effectiveness in chronic diffuse liver diseases (CDLD). This work was conducted at the Institute of gastroenterology, under the leadership of chief specialist of NAMS of Ukraine in the area of gastroenterology and nutrition , MD, professor Yury M. Stepanov. We evaluated the effectiveness of FORCELIV dose-dependence and its activity for different etiologies of CDLD. The data of the work result published in journal "Gastroenterology".

The results you can see on this link: PDF